Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NantKwest Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
NantKwest Inc, Medical Devices Deals, 2012 to YTD 2018 10
NantKwest Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
NantKwest Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Viracta Therapeutics Raises USD18.4 Million in Series B Financing 12
Conkwest Raises US$6.5 Million In Venture Financing 13
Partnerships 14
Altor BioScience Enters into Co-Development Agreement with NantKwest 14
NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 15
NantKwest Enters into Agreement with NanoCav 16
Sorrento Therapeutics Enters into Collaboration Agreement with Conkwest 17
Licensing Agreements 18
NantKwest Enters into Licensing Agreement with Viracta Therapeutics 18
NantKwest Amends its Licensing Agreement for NK-92 19
Inex Bio Enters into Licensing Agreement with Conkwest 20
Equity Offering 21
NantKwest Completes IPO 21
NantKwest Raises USD17 Million in Private Placement of Shares 23
Conkwest Raises USD71 Million in Private Placement of Shares 24
Conkwest Raises USD6.4 Million in Private Placement of Shares upon Exercise of Warrants 25
Conkwest to Raise USD48 Million in Private Placement of Common Stock 26
Acquisition 27
Conkwest Acquires Remaining 77.8% Stake in Inex Bio for USD8 Million 27
Conkwest Acquires 22.2% Stake in Inex Bio for USD0.25 Million 28
NantKwest Inc – Key Competitors 29
NantKwest Inc – Key Employees 30
NantKwest Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Corporate Communications 32
Jun 19, 2018: NantKwest Appoints Sonja Nelson As Chief Financial Officer 32
Sep 22, 2017: NantKwest Builds Financial and Commercial Expertise with the Appointment of Fred Driscoll to Its Board of Directors 33
Product News 34
06/06/2017: NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials Announced Addressing Multiple Cancer Types Across All Stages of Disease 34
Product Approvals 35
May 09, 2017: NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with Pancreatic Cancer 35
Mar 20, 2017: NantKwest Announces FDA Grant of Orphan Drug Designation for the Company’s aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma 36
Clinical Trials 37
Feb 13, 2018: Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Car–natural Killer) Cell Therapy in Glioblastoma 37
Oct 02, 2017: NantKwest Announces Successful First in Human Administration of CD16 High Affinity Natural Killer Cells 38
Jul 31, 2017: NantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies 39
Jan 23, 2017: Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer 40
Other Significant Developments 41
Jan 04, 2018: NantKwest to Host 3rd Annual Investor/Analyst Day Highlighting A Record Number of 15 INDs Authorized in 2017 Covering 12 Tumor Types with First In-Human Clinical Data of Safety and Early Signs of Clinical Activity of the Nant Cancer Vaccine 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
NantKwest Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NantKwest Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NantKwest Inc, Deals By Therapy Area, 2012 to YTD 2018 9
NantKwest Inc, Medical Devices Deals, 2012 to YTD 2018 10
NantKwest Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Viracta Therapeutics Raises USD18.4 Million in Series B Financing 12
Conkwest Raises US$6.5 Million In Venture Financing 13
Altor BioScience Enters into Co-Development Agreement with NantKwest 14
NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 15
NantKwest Enters into Agreement with NanoCav 16
Sorrento Therapeutics Enters into Collaboration Agreement with Conkwest 17
NantKwest Enters into Licensing Agreement with Viracta Therapeutics 18
NantKwest Amends its Licensing Agreement for NK-92 19
Inex Bio Enters into Licensing Agreement with Conkwest 20
NantKwest Completes IPO 21
NantKwest Raises USD17 Million in Private Placement of Shares 23
Conkwest Raises USD71 Million in Private Placement of Shares 24
Conkwest Raises USD6.4 Million in Private Placement of Shares upon Exercise of Warrants 25
Conkwest to Raise USD48 Million in Private Placement of Common Stock 26
Conkwest Acquires Remaining 77.8% Stake in Inex Bio for USD8 Million 27
Conkwest Acquires 22.2% Stake in Inex Bio for USD0.25 Million 28
NantKwest Inc, Key Competitors 29
NantKwest Inc, Key Employees 30
NantKwest Inc, Other Locations 31
NantKwest Inc, Subsidiaries 31
List of Figures
NantKwest Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NantKwest Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
NantKwest Inc, Medical Devices Deals, 2012 to YTD 2018 10